Recent News

• 05.28.2025 - Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
• 05.13.2025 - Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
• 05.05.2025 - Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
• 05.01.2025 - Rezolute to Participate in Upcoming Investor Conferences
• 04.25.2025 - Rezolute, Inc. Announces Closing of Underwritten Offering
• 04.23.2025 - Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
• 04.23.2025 - Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Recent Filings

• 05.13.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.28.2025 - 8-K Current report
• 04.28.2025 - EX-99.1 EX-99.1
• 04.23.2025 - EX-99.1 EX-99.1
• 04.23.2025 - EX-99.1 EX-99.1
• 04.23.2025 - 8-K Current report
• 04.23.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.23.2025 - 424B5 Prospectus [Rule 424(b)(5)]